The FDA approved an oral formulation of Novo Nordisk’s obesity drug Wegovy, marking the first GLP‑1 pill cleared for chronic weight management and for reducing cardiovascular risk similar to the injectable version. The decision was announced Monday and is expected to broaden access to a highly effective class of anti‑obesity therapies by enabling clinicians and patients who avoid injections to use a pill. Regulators granted the oral approval with indications mirroring the injectable Wegovy, including weight management and cardiovascular risk reduction. Novo Nordisk will now prepare commercial launch plans and manufacturing scale‑up to meet anticipated demand, while payers and clinicians navigate coverage and prescribing pathways for the new dosing form. For the biotech and pharmaceutical sectors, the approval validates oral GLP‑1 development strategies and could accelerate competition and lifecycle extensions across anti‑obesity pipelines as rivals ready oral candidates or reformulations.